Top
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
NPR News ·
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)
Originally published by
NPR News
Aggregated from a public feed. Read the original at the source for the publisher's full presentation.
View original on npr.orgContinue reading
